

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Docket Number (Optional)

42830-00234

Application Number

09/888,235

Applicant(s)


BLONDER et al.

Filing Date

June 22, 2001

Group Art Unit

1648



U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
Ble	A	6,201,072	3/13/01	RATHI et al.	525	415	AUG 29 2001 TECH CENTER 1600/2900
Ble	B	6,117,949	9/12/00	RATHI et al.	525	415	
Ble	C	6,004,573	2/21/99	RATHI et al.	424	426	
Ble	D	5,980,912	11/9/99	PODOLSKI et al.	424	278.1	
Ble	E	5,939,485	8/17/99	BROMBERG et al.	525	556	
Ble	F	5,912,000	6/15/99	PODOLSKI et al.	424	278.1	
Ble	G	5,861,174	1/19/99	STRATTON et al.	424	484	
Ble	H	5,902,110	5/11/99	ALFANO et al.	433	215	
Ble	I	5,702,717	12/30/97	CHA et al.	424	425	
Ble	J	4,971,956	1/20/90	SUZUKI et al.	514	55	

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
							YES	NO
Ble	K	WO 00/56362	9/28/00	WIPO				
	L	WO 00/56361	9/28/00	WIPO				
	M	WO 99/65521	12/23/99	WIPO				
	N	WO 99/32135	7/1/99	WIPO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Ble	O	Malakoff, "Aluminum is Put on Trial as a Vaccine Booster," Science, 2000. 288: 1323.
Ble	P	McNeela, E.A. et al. A mucosal vaccine against diphtheria: formulation of cross reacting material (CRM197) of diphtheria toxin with chitosan enhances and systemic antibody and Th2 responses following nasal delivery. 2001. Vaccine 19: 1188-1198.

EXAMINER

Dasgupta

DATE CONSIDERED

10/15/02

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

RECEIVED

TECH CENTER 1600/2900

AUG 29 2001

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Docket Number (Optional)

42830-00234

Application Number

09/888,235

Applicant(s)

BLONDER et al.

Filing Date

June 22,2001

Group Art Unit

1648

*EXAMINER
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Q	Seferian, P.G. and M.L. Martinez. Immune stipulating activity of two new chitosan containing adjuvant formulations. 2001. Vaccine 19: 661-668.
R	Edelman, R., An Overview of Adjuvant Use, in "Vaccine Adjuvants" Ed. D.T. O'Hagan, Humana Press, Totowa, NJ. 2000. 1-27.
S	Baldrige, J. R. et al. Monophosphoryl lipid A enhances mucosal and systemic immunity to vaccine antigens following intranasal administration. 2000. Vaccine 18: 2416-2425.
T	Goto, N. et al. Safety evaluation of recombinant cholera toxin B subunit produced by Bacillus brevis as a mucosal adjuvant. 2000. Vaccine 18: 2164-2171.
U	McCluskie, M. et al. Intranasal Immunization of Mice with CpG DNA Induces Strong Systemic and Mucosal Responses That Are Influenced by Other Mucosal Adjuvants and Antigen Distribution. 2000. Mol. Med. 6: 867-877.
V	Bacon, A. et al. Carbohydrate biopolymers enhance antibody responses to mucosally delivered antigens. 2000. Infection and Immunity. 68: 5784-5770.
W	Witschi, C. and R.J. Mrsny. In vitro Evaluation of Microparticles and Polymer Gels for Use as Nasal Platforms for Protein Delivery. 1999. Pharmaceutical Research 16: 382-390.
X	Barchfield, G.L. et al. The adjuvants MF59 and LT-K63 enhance the mucosal and systemic immunogenicity of subunit influenza vaccine administered intranasally in mice. 1999. Vaccine 17: 695-704.
Y	Isaka, M. et al. Systemic and mucosal immune responses of mice to aluminum-adsorbed or aluminum-non-adsorbed tetanus toxoid administered intranasally with recombinant cholera toxin B subunit. 1998. Vaccine 16: 1620-1626.
Z	Jabbal-Gill et al. Stimulation of mucosal and systemic antibody response against Bordatella pertussis filamentous haemagglutinin and recombinant pertussis toxin after nasal administration with chitosan in mice. 1998. Vaccine 16: 2039-2046.
AA	Horner, A.A. et al. Immunostimulatory DNA is a Potent Mucosal Adjuvant. 1998. Cell. Immunol. 190: 77-82.
BB	Lowrey, L. et al. Induction of Tolerance via the Respiratory Mucosa. Int. Arch. Allergy Immunol. 1998. 116: 93-102.

EXAMINER

Daogun hi

DATE CONSIDERED

10/15/2002

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Docket Number (Optional)

42830-00234

Application Number

09/888,235

Applicant(s)

BLONDER et al.

Filing Date

June 22, 2001

Group Art Unit

1648

TECH CENTER 1600/2900

AUG 29 2001

RECEIVED

*EXAMINER
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

CC

Yamamoto, S. et al. A nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity. 1997. Proceedings of the National Academy of Sciences of the United States of America. 94: 5267-5272.

DD

Neutra, M.R. et al. Antigen Sampling Across Epithelial Barriers and Induction of Mucosal Immune Responses. 1996. Ann. Rev. Immunol. 14: 275-300.

EE

Levi, R. et al. Intranasal immunization of mice against influenza with synthetic peptides anchored to proteosomes. 1995. Vaccine: 13: 1353-1359.

FF

Pizza, M. et al. A Genetically Detoxified Derivative of Heat-labile Escherichia Coli Enterotoxin Induces Neutralizing Antibodies Against the A Subunit. 1994. J. Exp Med 180, 2147-2153.

GG

Illum, L. et al. Chitosan as a Novel Nasal Delivery System for Peptide Drugs. 1994. Pharmaceutical Research 11: 1186-1189.

HH

Tamura, S. et al. Synergistic action of cholera toxin B subunit (and Escherichia coli heat-labile toxin B subunit) and a trace amount of cholera whole toxin as an adjuvant for nasal influenza vaccine. 1994. Vaccine 12: 419-426.

II

Holmgren, J. et al. Cholera toxin and cholera B subunit as oral-mucosal adjuvant and antigen vector systems. 1993. Vaccine 11: 1179-1184.

JJ

McGhee, J.R. et al. The mucosal immune system: from fundamental concepts to vaccine development. 1992. Vaccine: 10: 75-88.

KK

McNicholl, J.M. et al. Enhancement of HIV Type 1 Vaccine Immunogenicity by Block Copolymer Adjuvants. I. Induction of High-Titer, Long-Lasting, Cross-Reactive Antibodies of Broad Isotype, AIDS RESEARCH AND HUMAN RETROVIRUSES, Vol. 14, No. 16, 1998, pp. 1457-1471.

LL

Raghuvanshi, R.S. et al. Biodegradable delivery system for single step immunization with tetanus toxoid. International Journal of Pharmaceutics. 1993. 93: R1-R5.

EXAMINER

Waggoner

DATE CONSIDERED

10/15/2002

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

APR 12 2002

Docket Number (Optional)

42830-00234

Application Number

09/888,235

Applicant(s)

BLONDER - SUPPLEMENTAL -

Filing Date

June 22, 2001

Group Art Unit

1648

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
Doc	A	2001/0044416 A1	11/22/01	McCLUSKIE et al.	514	44	
	B	6,239,116 B1	5/29/01	KRIEG et al.	514	44	
	C	6,218,148 B1	4/17/01	ZSEBO et al.	435	69.5	
	D	6,207,646	3/27/01	KRIEG et al	514	44	
	E	6,086,899	7/11/00	BALASUBRAMANIAN et al.	424	280.1	
	F	5,071,644	12/10/01	VIEGAS et al.	514	772.7	
	G	5,593,683	1/14/97	VIEGAS et al.	424	427	

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
							YES	NO
Doc	H	WO 01/22972 A2	4/4/01	PCT				
	I	WO 01/12218 A1	2/22/01	PCT				
	J	WO 98/06438	2/19/98	PCT				
	K	WO 97/20576	6/12/97	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Doc	L	Lemieux, P. et al., A combination of poloxamers increases gene expressions of plasmid DNA in skeletal muscle, GENE THERAPY, 2000, Vol. 7, pp.986-991.
	M	Miyazaki, S. et al., Sustained-Release and Intragastric-floating Granules of Indomethacin Using Chitosan in Rabbits, CHEM. PHARM. BULL, 1998 Vol. 36 (10), pp. 4033-4038.

EXAMINER

Doc

DATE CONSIDERED

10/15/02

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

105 #5